Alta Backs Anesiva

Alta Partners has invested $25 million in drug developer Anesiva Inc. (Nasdaq: ANSV) as part of a common stock offering. Anesiva, a South San Francisco-based company, has priced a stock offering of 11.1 million shares at $4.05 each. The company expects proceeds of about $42.9 million after underwriting discounts and commissions, or up to $47.7 million if the underwriters fully exercised overallotment options of about 1.2 million shares.